Clinical trial
Geodon for the Treatment of Refractory Social Anxiety Disorder
NCT00215150 · Duke University, Other · Completed
Key facts
| NCT number | NCT00215150 |
|---|---|
| Title | Geodon for the Treatment of Refractory Social Anxiety Disorder |
| Official title | Ziprasidone for the Treatment of Refractory Social Anxiety Disorder |
| Acronym | SAD |
| Lead sponsor | Duke University, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Social Anxiety Disorder |
| Intervention type | Drug |
| Interventions | Ziprasidone, Sertraline |
| Enrollment | 51 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: